Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Terminated Phase 1Phase 2 Interventional Results available

Convalescent Plasma vs. Standard Plasma for COVID-19

NCT04344535
Conditions
COVID
Interventions
Convalescent Plasma, Standard Donor Plasma
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
COVID-19
Interventions
Convalescent Plasma, Best Supportive Care
Biological · Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
COVID-19
Interventions
Convalescent Plasma
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
COVID-19
Interventions
COVID Convalescent Plasma
Biological
Lead sponsor
Gailen D. Marshall Jr., MD PhD
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Anti-Sars-CoV-2 Convalescent Plasma
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
26
States / cities
Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Communicable Diseases, Communicable Diseases, Emerging, Emerging Infectious Diseases, Infection
Interventions
Plasma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma

NCT04497779
Conditions
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Covid19
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Conditions
COVID-19
Interventions
Convalescent plasma
Biological
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
16 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Completed Phase 3 Interventional Results available

Convalescent Plasma in Outpatients With COVID-19

NCT04355767
Conditions
Covid19
Interventions
Convalescent Plasma, Saline
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
53
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more
Conditions
Severe Acute Respiratory Syndrome, COVID
Interventions
SARS-CoV-2 plasma
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Coronavirus, COVID-19, Convalescent Plasma
Interventions
Convalescent Plasma
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
16 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
COVID19
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
12
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 9 more
Conditions
COVID-19, SARS-CoV 2
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Conditions
COVID-19
Interventions
Convalescent Plasma
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Terminated Phase 2 Interventional Results available

Use of Convalescent Plasma for COVID-19

NCT04408040
Conditions
COVID
Interventions
Convalescent Plasma
Biological
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia